Abstract
Introduction
Heart failure (HF) is a progressive, chronic myocardial disorder involving various pathophysiological pathways. It has recently been reported that six major pathways are involved, both in the development and the progression of HF [1] . Various management strategies including medical treat-Hamza Sunman et al., Effect of CRT on the pathogenesis of heart failure ment and/or device implantation are aimed at either slowing down or reversing the disease process. Cardiac resynchronization therapy (CRT) is a valuable interventional therapeutic option in patients with systolic HF and left ventricular (LV) conduction disturbances, as it decreases the chances of both morbidity as well as mortality [2, 3] . Yet, up to 30-40% of the patients do not benefit from CRT implantation for several reasons [4, 5] . Although several studies using circulating biomarkers have been carried out to identify patient responsiveness to CRT [6] [7] [8] [9] [10] , none could assess all the predefined pathophysiological pathways as a whole in the same patient population. Hence, the aim undertaken was to evaluate the relationship of CRT responsiveness with six different pathophysiological pathways of HF using surrogate biomarkers.
Methods
A total of 44 patients diagnosed with systolic HF, who underwent CRT implantation were included in the study. The inclusion criteria were as follows: New York Heart Association (NYHA) class II-III symptoms despite optimal tolerable medical therapy, LV ejection fraction of ≤ 35%, and a QRS duration of > 120 ms either resulting from bundle branch block or intraventricular conduction delay. All subjects included in the study had to meet the inclusion criteria. Patients were excluded if they had atrial fibrillation (AF), acute or chronic inflammatory or infectious disease, recent (≤ 30 days) clinical diagnosis of acute coronary syndrome, acute decompensated HF, or had recently (< 6 months) undergone a coronary revascularization procedure or a coronary by-pass surgery. The recorded baseline characteristics included patient demographics, QRS duration, etiology of cardiomyopathy, medical history in relation to hypertension, diabetes, smoking, AF, and the use of the medications prescribed including beta-blockers, angiotensin-converting enzyme inhibitors, spironolactone, digoxin, and diuretics. The study protocol was approved by the Ethics Committee. Written informed consent was obtained from all patients.
Serial echocardiography was performed at both times, before and after CRT implantation in order to assess the degree of LV reverse remodeling and changes in cardiac function. LV end-systolic volume, LV end-diastolic volume, and ejection fraction were assessed using Simpson's equation. The severity of mitral regurgitation was graded semi-quantitatively by color flow Doppler in the conventional parasternal long axis and by the images of the apical 4-chambers. Living patients were classified as CRT responders if they showed a ≥ 15% decrease in LV end-systolic volume (compared to baseline) at the 12-month follow-up [11] .
The LV lead was placed in the coronary sinus in order to achieve permanent epicardial stimulation as described earlier [12] . CRT device and lead placements were accomplished in all the subjects without major complications (Medtronic, St. Paul, MN, USA and Biotronik, Berlin, Germany). The pacing mode was set at DDD which is programmed to maximize biventricular pacing, and the atrioventricular and interventricular delays were optimized using Doppler echocardiography. Coronary sinus lead position, pacing mode, and the programming of timing intervals were evaluated at 1, 3, 6, and 12 months after CRT implantation.
Blood samples were obtained from the patients after a 30-min bed rest, both before CRT and at the 12-month follow-up visit and were stored at −80°C until used. Biomarkers that played a role in the pathogenesis of HF were classified into six groups on the basis of the data obtained from previous studies [1] . The biomarkers that were assessed included interleukin (IL)-4 (BMS225INST, Bendermed, Austria), IL-6 (BMS213INS, Bendermed, Austria), tumor necrosis factor-alpha (TNF-a) (BMS223INST, Bendermed, Austria) and high-sensitive C-reactive protein (hsCRP) (EIA3954, DRG, Austria) for inflammation; oxidized low density lipoprotein (oxLDL) (K7810, Immune Diagnostic, Germany), myeloperoxidase (MPO) (K6631, Immune Diagnostic, Germany) and uric acid (routine) for oxidative stress; matrix metalloproteinase (MMP)-2 (ELH-MMP2-001, RayBiotech, Austria), MMP-9 (BMS2016/2, Bendermed, Austria), galectin-3 (BMS279/2, Bendermed, Austria) and procollagen III N-terminal propeptide (prokol--3NT) (E0573Hu, Uscnk, Austria) for extracellular remodeling; the neurohormones endothelin-1 (BI20052, BIOMEDICA, Canada) and chromogranin-A (RSCYK070R, Biovendor, Germany) by ELISA; troponin T (routine), creatine kinase MB fraction (CK-MB) (routine) for myocyte damage; and B-type natriuretic peptide (BNP) (routine) for myocyte stress. Blood samples from all patients were processed according to instructions given by the manufacturer and were spectrophotometrically read on a SpectraMax M2 reader (Molecular Devices, Inc., Silicon Valley, CA, USA).
Statistical analysis
All statistical analyses were performed using SPSS for Windows (ver. 20, IBM SPSS Inc., Chicago, IL). A p-value < 0.05 was considered to Cardiology Journal 2018, Vol. 25, No. 1 be statistically significant. Quantitative variables with normal distribution were represented as mean ± standard deviation and were analyzed by the Student t-test; whereas non-normally distributed variables were represented as median-interquartile range (IQR) and were analyzed using the twotailed Mann-Whitney U-test. Categorical data were expressed as proportions and compared using c 2 test. Initially, a univariate analysis was performed at baseline levels to investigate the association between biomarkers and the incidence of CRT--response. Subsequently, a multivariate analysis (backward LR) was also performed including those variables which had a p-value ≤ 0.25 in the univariate analysis. The receiver-operating characteristic (ROC) curve was used to evaluate the performance of biomarker levels to predict the response to CRT. An optimal cut-off point was chosen as the sensitivity and specificity were maximized. The correlation coefficients that were reported were based on a non-parametric method (Spearman rank). 
Results
A total of 44 patients (mean age 61.6 ± 11.7 years, 14 females) with successful implantation of biventricular implantable cardioverter defibrillators were included in the study. Out of these, 32 (72.7%) patients were considered responders while the remaining 12 (27.2%) patients were nonresponders, as they did not respond to CRT. Out of the total patients included, left bundle branch block was present in all 32 (100%) responders and in 9 (75%) non-responders. Another baseline demographic, electrocardiographic and echocardiographic parameters were comparable in both responders and the non-responders (Table 1) . Considerable left ventricle reverse remodeling was seen in all the responders with a mean decrease in LV end-systolic volume index from 75.96 ± 29.9 mL/m 2 to 58.56 ± 24.7 mL/m 2 (p = 0.001) and a mean increase in LV ejection fraction from 27.0 ± 5.47% at baseline to 35.44 ± 8.08% at 12-month follow-up (p = 0.001). While the QRS width showed a significant decrease in the responders from 162. Hamza Sunman et al., Effect of CRT on the pathogenesis of heart failure Analysis of the responders showed that, at the 12-month follow-up visit, levels of IL-6, MPO, oxLDL, MMP-2, galectin-3, troponin T, and BNP were significantly lower than the baseline; while the levels of IL-4, hsCRP, TNF-a, uric acid, MMP-9, prokol-3NT, endothelin-1, chromogranin A and CK-MB did not show a significant change. On the other hand, in the non-responders, the levels of MPO and MMP-2 were lower; uric acid level was higher and the levels of IL-4, IL-6, hsCRP, TNF-a, oxLDL, MMP-9, prokol-3NT, galectin-3, endothelin-1, chromogranin A, troponin T, CK-MB, and BNP did not show a significant change at 12-month follow-up ( Table 2) .
Out of the pathways involved in the pathogenesis of HF, significant changes were observed in three of them, i.e. myocyte stress, extracellular matrix (ECM) remodeling, and oxidative stress, of the six pathways that were studied. At follow-up, no significant changes were seen in the inflammatory, myocyte injury, and neurohormonal pathways. On repeated measures, two-way ANOVA showed that the changes in myocyte stress markers had the greatest effect size (effect size = 0.357; p = 0.001) followed by changes in markers of ECM remodeling (effect size = 0.343; p = 0.015) and oxidative stress (effect size = 0.247; p = 0.039) ( Table 3) .
In the present study, out of 44 patients included, 33 (75%) were clinical responders (improvement NYHA class ≥ 1). When analysis was performed in the clinical responders on the basis of clinical improvement, a decrease in levels of IL-6, MPO, oxLDL, galectin-3, MMP-2, MMP-9, endothelin-1, troponin T, and BNP was found while levels of IL-4, TNF-a, hsCRP, uric acid, prokol-3NT, chromogranin A, and CK-MB did not show any change. Similar findings were obtained with ANOVA analysis, viz., surrogate biomarkers of oxidative stress, ECM remodeling, and myocyte stress showed a significant improvement in clinical responder patients. In the study population, 27 patients had non-ischemic etiology for HF. Of these, 22 (81.5%) were found to be responders. Biochemical analysis in the patients with HF due to nonischemic etiology revealed that levels of IL-6, TNF-a, MPO, MMP-2, galectin-3, and BNP decreased; while levels of IL-4, hsCRP, uric acid, oxLDL, MMP-9, prokol-3NT, endothelin-1, chromogranin A, troponin T and CK-MB levels showed no improvement. When the biomarkers were considered as a pathway group, a significant improvement was observed in oxidative stress, ECM remodeling, and myocyte stress biomarker groups (data not shown). . The most sensitive BNP and oxLDL cut-off levels for CRT response determined by ROC analysis were 682 pg/mL and 37.5 ng/mL, respectively. In order to further explore the relationships between the investigated biomarkers, a detailed correlation analysis was performed (Table 4) 
Discussion
In the present study, it was found that CRT is associated with an improvement in the biomarkers of myocyte stress, ECM remodeling, and oxidative stress, besides having a beneficial effect on the clinical and echocardiographic parameters. The most prominent change was seen in the markers of myocyte stress, followed by those of oxidative stress and ECM remodeling. However, the biomarkers of inflammation, neurohormones, and myocyte injury did not show a statistically significant change.
Cardiac remodeling mainly results in cardiac dysfunction. It involves a pathophysiological substrate for its onset and progresses to ventricular dysfunction. Consequently, cellular and molecular changes occur, which result in a progressive loss of ventricular function and dilatation leading to QRS prolongation. QRS expansion leads to molecular Table 2 . Serum levels of biomarkers before and after cardiac resynchronization therapy. LDL -low density lipoprotein; MMP -matrix metalloproteinase; MPO -myeloperoxidase; Prokol-3NT -procollagen III N-terminal propeptide; TNF-a -tumor necrosis factor alpha Hamza Sunman et al., Effect of CRT on the pathogenesis of heart failure polarization and re-arrangement of myocardial blood [13, 14] . The studies on the pathogenesis of HF have shown that in the process of cardiac dysfunction, inflammation, oxidative stress, ECM remodeling, neurohormones, myocyte damage, and myocyte stress play a role [1, 15] . It is important to study the changes in the pathophysiological process after resynchronization between the ventricular walls. Cardiac resynchronization therapy reduces BNP and troponin levels by decreasing intraventricular pressure and myocardial wall tension [16] . Comprehensive investigations have been carried out on the biological role and the potential clinical applications of the natriuretic peptides. Many studies have shown that a significant decrease in BNP levels occurs after CRT, resulting in a good prognosis [17] . The results obtained in this study are comparable to those of the previous studies. It has also been found that the positive effects of CRT on myocyte stress are accompanied by a decrease in BNP levels. Though a significant decrease was seen in myocyte stress, yet there were only limited changes seen in the biomarkers of myocyte damage after CRT. The results of the present study are consistent with those of previous research which has shown that an increase in ventricular wall tension results in much lower subclinical myocardial damage when compared to ischemic heart disease [18] .
Ventricular remodeling plays a significant role in the progression to HF. The ECM provides a skeleton for myocytes and determines their size and shape. The ECM is a metabolically active structure with a continuous turnover of its elements so that a dynamic balance between the synthesis and degradation of collagen is maintained. Myofibroblasts function to regulate collagen turnover and respond to stimuli like a mechanical stretch, wall stress, autocrine, and paracrine factors. The response of the myofibroblasts to these factors results in an imbalance between MMPs and their inhibitors, which is in turn associated with ventricular dysfunction and dilatation [19] . Any abnormality in collagen metabolism may also BNP -B-type natriuretic peptide; CK-MB -creatine kinase MB fraction; hsCRP -high sensitive C-reactive protein; LDL -low density lipoprotein; MMP -matrix metalloproteinase; Prokol-3NT -procollagen III N-terminal propeptide; TNF-a -tumor necrosis factor alpha Table 4 . Correlation analysis between baseline values of biomarkers assessed in the study. MMP -matrix metalloproteinase; MPO -myeloperoxidase; Prokol-3NT -procollagen III N-terminal propeptide; TNF-a -tumor necrosis factor alpha prove to be deleterious to cardiac functions as the resultant fibrotic changes can result in impairment of ventricular function [20] . Cardiac synchronization decreases the mechanical tension and stress imposed on the left ventricle. As the process of reverse remodeling begins, an improvement in ECM metabolism and a decrease in the levels of ECM remodeling markers (like galectin-3, prokol--3NT, and MMPs) is also seen [21, 22] . In the present study, a significant decrease was observed in the levels of MMP-9 and galectin-3. However, the changes in the levels of MMP-2 and procollagen were not significant. Some previous studies have also demonstrated that systemic MMP levels may not exactly reflect MMP metabolism in the cardiac muscle; while other studies have shown that an increase in collagen precursors may actually reflect reverse cardiac remodeling [23] .
Oxidative stress results from an imbalance between the formations of reactive oxygen species (ROS) and endogenous antioxidant defense mechanisms. The imbalance in oxidative metabolism has deleterious effects on the progression to HF. Oxidative stress can damage cellular proteins and lead to myocyte apoptosis and necrosis. Since direct quantification of reactive oxygen species in humans is difficult, indirect markers of oxidative stress have been developed that include molecules like oxLDL, uric acid, and MPO. An increase in the level of plasma oxLDL in a peripheral blood sample may indicate an increase in ROS in the failing myocardium or in the poorly perfused peripheral muscles of patients with HF. Uric acid is a predictor of poor prognosis in patients with HF. During HF, the levels of circulating MPO increase and correlate with disease intensity [15, 24] . On the contrary, the improvements in the clinical status of patients and reverse remodeling after resynchronization therapy are associated with a decrease in oxidative stress [25, 26] . The levels of biomarkers indicating oxidative stress were improved at the end of the follow-up period in the present study, which is consistent with these findings. Another significant finding is that the oxLDL and BNP were found to be independent predictors for CRT response. Since the present study is the first of its kind investigating the oxLDL in the CRT patients, the findings of this study form a base for further studies.
It has been established that HF is associated with systemic inflammation and that it involves the interplay between pro-inflammatory and inhibitory cytokines. It is hypothesized that CRT reduces inflammation and that it may be one of the several factors responsible for improving the symptoms of HF. However, the available literature reports conflicting results and suggests that the role of CRT in reducing inflammation is not uniform, rather it shows variations due to different interactions occurring during the disease process [27, 28] . It was also found in the present study that no significant change occured in the levels of inflammatory biomarkers, except in IL-6.
It is well known that during HF the neurohormones increase as a response to a vasoconstriction due to reduced peripheral flow, and this response results in further myocardial damage while also worsening cardiac functions [29] . Though the effect of neurohormones in the pathogenesis of HF was first identified more than 50 years ago, its role in dyssynchrony remains unclear [1] . When the power of contraction of the heart decreases, the resultant decline in peripheral circulation induces an increase in catecholamine and endothelin levels in order to restore circulation. Previous studies have demonstrated that increased endothelin-1 levels are associated with both ventricular and vascular fibrosis. The level of chromogranin-A, which increases circulation may be associated with neuroendocrine activation and to the clinical severity in patients with HF [29] [30] [31] . However, no decrease in levels of endothelin-1 and chromogranin-A after CRT implantation was found in the present study, suggesting that the optimal medical therapy, particularly the beta-blockers, may affect the concentration of neurohormones in patients with HF.
Limitations of the study
This study had a few limitations, firstly, this was a small-sized preliminary and hypothesis generating study rather than a cause-effect association study. The small sample size especially poses difficulty in statistical analysis for the prediction of CRT response and the correlation between each biomarker. In addition, according to the current guidelines, class I recommendation has been introduced for CRT in patients with QRS duration ≥ 150 ms and this therapy is not recommended for the patients whose QRS duration is less than 130 ms. However, only two-thirds of patients included in the present study met this criterion. Secondly, six pathophysiological pathways and more than 30 biomarkers are associated with both development and progression of HF. The pathways were investigated together in order to understand how they are affected by CRT therapy using a limited number of biomarkers. As the blood samples were obtained only at two points in time, i.e., at the time of initiation of the study and at 12-month Cardiology Journal 2018, Vol. 25, No. 1 follow-up, it is also possible that some information on these markers may have been missed during the period in between. Thirdly, certain pathways are not independent but are interdependent. The inflammatory, oxidative and remodeling processes constitutes complex chemical reactions that involve many molecules; therefore eliminating an individual variation among the circulating biomarkers is almost impossible. In addition, some biomarkers may also be indicative of multiple pathophysiological pathways.
Conclusions
In the present study, a significant reduction was observed only in the biomarkers of myocardial stress, ECM remodeling and oxidative stress among all the CRT responder subjects. Nevertheless, further large-scale studies are required to confirm the results of this preliminary, hypothesis generating study.
